Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, animal health) in North America and Europe. The company operates through two reportable segments: Healthcare Distribution and Technology.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended Sept 30, 2006 |
Nine Months Ended Sept 30, 2006 |
|---|---|---|
| Net Sales | $1,272,020 | $3,654,161 |
| Gross Profit | $361,006 | $1,058,068 |
| Gross Margin | 28.4% | 29.0% |
| Operating Income | $62,675 | $200,341 |
| Net Income | $39,285 | $100,762 |
| Diluted EPS (Continuing Ops) | $0.44 | $1.34 |
| Cash from Operations (9mo) | $64,626 | |
| Total Debt | $499,654 | |
| Working Capital | $792,404 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.0% ($146.7 million) for the quarter and 11.0% ($361.4 million) for the nine months compared to the prior year. Growth was driven by organic volume increases and acquisitions, partially offset by foreign currency fluctuations in the nine-month period.
- Profitability: Operating income rose 7.4% for the quarter and 12.1% for the nine months. Gross margins improved slightly across both segments due to favorable sales mix and margin management.
- Discontinued Operations: The company sold its Hospital Supply Business in April 2006, resulting in a $32.3 million pre-tax loss on the sale. This is classified as a discontinued operation and is excluded from continuing operations results.
- Acquisitions: Significant acquisitions included NLS Animal Health (March 2006) and the "Darby Group" (dental and medical distributors) in Q3 2006, contributing to revenue growth.
- Accounting Changes: The company adopted FAS 123(R) for stock-based compensation effective January 1, 2006, using the modified retrospective application method. Prior period results have been adjusted to reflect this change.
Guidance, Outlook, and Risks
- Outlook: Management expects demand for products and services to remain consistent. The company anticipates investing approximately $20.0 million in capital projects for the remainder of the fiscal year to modernize facilities and integrate acquisitions.
- Liquidity: The company maintains a $300.0 million revolving credit facility with no borrowings outstanding as of September 30, 2006. Cash and cash equivalents totaled $176.1 million.
- Stock Repurchases: Under an authorized program, the company had repurchased $114.2 million of stock as of September 30, 2006, with $85.8 million remaining available.
- Risks and Contingencies:
- Legal: Approximately 49 product liability cases are pending; management believes these are covered by insurance or indemnification and will not have a material adverse effect.
- Market Risk: Exposure to foreign currency exchange rates and variable interest rates on debt.
- Integration: Risks associated with integrating recent acquisitions (NLS, Darby Group) and implementing new ERP systems.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of the NLS Animal Health and Darby Group acquisitions and their contribution to organic growth targets.
- Discontinued Operations: Confirm that the $32.3 million loss on the Hospital Supply Business sale is fully accounted for and that no further contingent payments are expected.
- Working Capital Trends: Monitor the increase in inventory levels ($572.6 million vs. $505.5 million prior year) and accounts receivable days sales outstanding (42.5 days) to ensure efficient capital management.
- Debt Obligations: Review the terms of the $240 million convertible notes (due 2034) and $130 million senior notes (due 2009), including conversion triggers and interest rate exposure.
- Stock-Based Compensation: Assess the impact of the new FAS 123(R) standard on future earnings, noting $44.3 million in unrecognized compensation cost.